Figure 1
From: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
Patient disposition across the entire study including addition of dexamethasone.
Figure 1 | Blood Cancer Journal
From: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
Patient disposition across the entire study including addition of dexamethasone.
